EcoDrugPlus

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSLACG00000018602
Gene Symbol: HTR3A
4 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSLACG00000018595
Gene Symbol: HTR3B
4 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSLACG00000010511
Gene Symbol: HTR5A
4 Cross references
210 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSLACG00000011170
Gene Symbol: HTR6
3 Cross references
114 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSLACG00000000885
Gene Symbol: HTR7
4 Cross references
220 Possible Orthologues:

60s Acidic Ribosomal Protein P1 Pseudogene

Ensembl ID : ENSLACG00000014113
Gene Symbol: LOC102352213
2 Cross references
376 Possible Orthologues:

60s Ribosomal Protein L22-Like

Ensembl ID : ENSLACG00000018322
Gene Symbol: LOC102352899
2 Cross references
372 Possible Orthologues:

60s Ribosomal Protein L23

Ensembl ID : ENSLACG00000004430
Gene Symbol: LOC102348310
4 Cross references
342 Possible Orthologues:

60s Ribosomal Protein L23-Like

Ensembl ID : ENSLACG00000006781
Gene Symbol: LOC102350741
4 Cross references
342 Possible Orthologues:

60s Ribosomal Protein L29-Like

Ensembl ID : ENSLACG00000018622
Gene Symbol: LOC106702682
4 Cross references
495 Possible Orthologues:

60s Ribosomal Protein L37 Pseudogene

Ensembl ID : ENSLACG00000014792
Gene Symbol: LOC102366424
1 Cross references
111 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSLACG00000009313
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).